CytoVeris Inc.
CytoVeris Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at CytoVeris Inc..
CytoVeris Inc. is a company.
Key people at CytoVeris Inc..
Key people at CytoVeris Inc..
CytoVeris Inc. is a medical device company developing AI-powered intraoperative imaging technologies to enhance cancer detection and surgical decision-making. Founded in 2018 and based in Farmington, Connecticut, it leverages optical technologies, biochemical knowledge of cancer changes, and artificial intelligence to provide surgeons with tools for precise tumor resection, aiming to enable complete cancer removal in a single surgery and improve patient outcomes.[1][2][3] The company serves surgeons and cancer patients, particularly in oncology procedures like bladder cancer treatment, addressing the problem of incomplete tumor removal that often requires repeat surgeries. With around 21-25 employees and $8.8 million in revenue, CytoVeris has secured under $5 million in funding, including a National Cancer Institute SBIR Phase 1 grant in 2021 for validating its tech in bladder cancer applications, indicating steady early growth momentum.[2][3]
CytoVeris was founded in 2018 in Farmington, Connecticut, driven by a mission rooted in scientific passion and compassion for cancer patients.[2][3] While specific founders are not detailed in available sources, the company's emergence aligns with advancing optical tech and AI convergence for surgical applications, sparked by recognition of biochemical alterations in carcinogenesis that challenge traditional visualization.[1][2] Early traction includes a 2021 National Cancer Institute Small Business Innovation Research Phase 1 grant to validate its AI-powered platform for bladder cancer, marking a pivotal validation moment, alongside partnerships like robotics integration for surgical guidance announced in September (year unspecified).[1][2]
CytoVeris stands out in intraoperative cancer imaging through these key strengths:
CytoVeris rides the wave of AI-driven precision medicine and intraoperative imaging trends, where real-time visualization addresses the 20-50% incomplete resection rates in cancers like bladder tumors, amplified by post-pandemic demands for efficient, one-and-done surgeries.[2] Timing is ideal amid surging medtech investments in AI optics (e.g., hyperspectral imaging) and robotics, fueled by aging populations and rising cancer incidences—market forces projecting the surgical imaging sector to exceed $10B by 2030. By influencing ecosystems through SBIR grants and partnerships, CytoVeris contributes to broader adoption of AI in oncology, potentially setting standards for accessible, high-accuracy tools that bridge research labs to ORs.[1][2][3]
CytoVeris is poised for expansion via additional grants, clinical trials, and robotic partnerships, targeting FDA clearance and commercialization of its platform amid booming AI-medtech demand. Trends like multimodal imaging and generative AI for diagnostics will accelerate its trajectory, potentially scaling revenue beyond $8.8M through oncology expansions (e.g., beyond bladder cancer). Its influence may evolve from niche innovator to ecosystem shaper, empowering surgeons with "superhuman" vision to redefine one-surgery cures—echoing its core passion for science-fueled patient compassion.[1][2][3]
